Approximately half of all patients with chronic conditions do not take their medications as prescribed. Poor adherence to medications has many negative health consequences, and increases health care costs in the U.S. by an estimated $100 billion per year or more. To help providers improve medication adherence among their patients, Harvard Pilgrim has developed four reports for patient populations with diabetes, acute myocardial infarction, asthma, or rheumatoid arthritis.
Using pharmacy claims data, Harvard Pilgrim identifies patients with gaps in their prescription fill history and makes this available to the members' PCPs to help improve adherence rates and clinical outcomes.
Four adherence reports available
- Diabetes multiple prescriber report — This report focuses on patients with diabetes who have had more than five prescribers in the previous six months and includes a graphical representation of prescribers and medication dispensed. The report, which aids PCPs in identifying potential drug duplication and non-compliance is mailed semi-annually in January and June, and is also available through a secure electronic file transfer.
- Cardiac medication adherence report — Also mailed semi-annually in January and June and available through a secure electronic file transfer, this report lists and graphically displays the fill history for all cardiac medications prescribed after a heart attack and provides the medication possession ratio (MPR) for beta blocker therapy. This MPR information alerts the PCP to potential non-compliance to beta blocker therapy.
- Asthma adherence report — This report lists the number of controller and reliever medications prescribed and filled, as well as the name of the prescribing physician. PCPs can better assess asthma control by examining the ratio of controller to reliever medications provided in this report, which is mailed annually in September.
- Rheumatoid arthritis adherence report — Our newest report, the rheumatoid arthritis adherence report is also mailed annually in September to PCPs whose patients have been diagnosed with rheumatoid arthritis, but have not been prescribed a disease-modifying anti-rheumatic drug (DMARD). DMARDs can be an important part of a rheumatoid arthritis treatment plan, since they slow the progression of the disease.
We’re striving to make these reports as valuable as possible, providing actionable claims-based prescription data, which might not otherwise be available, in an easy-to-read format. For more information on any of these reports, please contact our Clinical Programs Department at 800-287-9793.